HumGel™
Advantages
- 100% natural ECM — human tumor‑derived; no animal‑derived materials.
- Room‑temperature stable and ready‑to‑use — no strict temperature control required.
- Physiological relevance — more accurate cell behavior and improved drug testing.
- Neutral, stable pH and automation‑friendly for high‑throughput workflows.
- Ethically sourced — reduced ethical concerns with human‑specific functionality.
Using human tumor‑derived matrices can offer more representative in vitro conditions, enhancing the credibility of cancer research and drug testing.
Human Tumor-Derived ECM
Key components
Collagens
Collagen IV, XII, XIV — structural integrity for the tumor microenvironment.
Basement membrane
Laminin, Nidogen, Heparan sulfate proteoglycans for cell–matrix interactions.
Signals & modulators
EGF, Tenascin‑C, cytokines & growth factors for biologically active signaling.
Human‑specific
~60% protein profile difference from Matrigel, reflecting authentic human composition.
HumGel™
Product types
Liquid MyoGel
Vials: 1 ml, 5 ml, 10 ml — flexible volumes for any scale of research.
Pre‑coated plates
12‑, 96‑, and 384‑well formats for immediate use in your assays.
Custom configurations
Tailor matrix density and format to your cell type and assay needs.
Precision that drives discovery
Applications
Scratch wound assay
Reproducible wound-healing models for reliable invasion and migration data.
Spheroid invasion assay
Model real tumor behavior in 3D. Generate consistent spheroids from cell lines or patient-derived samples.
High-throughput drug testing
Scalable workflows for rapid compound evaluation and comparison in biologically relevant setting.
3D microfluidic chip
Bring the human tumor microenvironment on-chip for truly predictive drug response.
MyoGel by HumGel™ vs. Mouse Basement Membrane Matrix
Comparison
| Attribute | Human tumor-derived Matrix (MyoGel) | Mouse Basement Membrane Matrix |
|---|---|---|
| Stability | Room‑temperature stable | Requires cold chain |
| Biological relevance | Human tumor‑derived | Mouse‑derived |
| pH | Neutral & stable | Less stable |
| Automation | Automation‑friendly | Challenging |
| Predictive behavior | More accurate cell behavior | Often less predictive |
| Ethics | Reduced ethical concerns | Animal origin |
Summary of qualitative differences reported in customer and literature use‑cases.
Research behind Myogel
Selected references
- Salo, T., et al., BMC Cancer, 2015.
- Al‑Samadi, A., et al., Oncotarget, 2017.
- Hoornstra, D., et al., In Vivo, 2018.
- Hoque Apu, E., et al., Exp Cell Res, 2018.
- Salo, T., et al., Phil. Trans. R. Soc. B, 2018.
- Väyrynen, O., et al., Exp Cell Res, 2018.
- Al‑Samadi, A., et al., Exp Cell Res, 2019.
- Charbonneau, A.M., et al., Biotechnol J, 2019.
- Naakka, E., et al., J Vis Exp, 2019.
- Tuomainen, K., et al., Cancers, 2019.
- Aquino, I.G., et al., Arch Oral Biol., 2020.
- Peltonen, J., et al., Anticancer Res., 2020.
- Tuominen, H., et al., Virol J, 2020.
- Wahbi, W., et al., Exp Cell Res, 2020.
- Tuomainen, K., et al., Sci Rep, 2021.
- Barmaki, S., et al., Biomater Biosyst., 2022.
- Lindfors, L., et al., Anal Chim Acta, 2022.
- Sieviläinen, M., et al., Front Immunol., 2022.
- Hyytiäinen, A., et al., Cancer Cell Int., 2023.
- Koivikko, T., et al., Front Pharmacol., 2023.
- von Hofsten, S., et al., Front Pharmacol., 2023.
- Wahbi, W., et al., Transl Oncol., 2023.
- Korelin, K., et al., Biomed Pharmacother, 2024.
- Giedraityte Z., et al., Transl Oncol., 2025.
Click to open. Full citations available on request.
Our partners
Partner with us
Shape the future of cancer research
Real progress happens through collaboration. We invite researchers, clinicians, and pharmaceutical innovators to join us in making more predictive cancer models the new standard.
Contact us
Let's connect
For orders, quotes, or technical details, reach out to our team.
Email: info@humgel.com
Web: www.humgel.com